Bookmark
Forward
QuickView for Deslanoside (compound)
PubChem
| Name: | Deslanoside |
|---|---|
| PubChem Compound ID: | 11766385 |
| Description: | Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata. |
| Molecular formula: | C47H74O19 |
| Molecular weight: | 943.079 g/mol |
DrugBank
Identification
| Name: | Deslanoside |
|---|---|
| Name (isomeric): | DB01078 |
| Drug Type: | small molecule |
| Description: | Deacetyllanatoside C. A cardiotonic glycoside from the leaves of Digitalis lanata. |
| Brand: | Cedilanid-d, Deacetyllanatoside C |
| Category: | Cardiotonic Agents, Enzyme Inhibitors, Anti-Arrhythmia Agents |
| CAS number: | 17598-65-1 |
Pharmacology
| Indication: | For the treatment and management of Congestive cardiac insufficiency, arrhythmias and heart failure. |
|---|---|
| Pharmacology: | Deslanoside is a cardiac glycoside used to treat congestive heart failure and supraventricular arrhythmias due to reentry mechanisms, and to control ventricular rate in the treatment of chronic atrial fibrillation. |
| Mechanism of Action: |
Deslanoside inhibits the Na-K-ATPase membrane pump, resulting in an increase in intracellular sodium and calcium concentrations. Increased intracellular concentrations of calcium may promote activation of contractile proteins (e.g., actin, myosin). Deslanoside also acts on the electrical activity of the heart, increasing the slope of phase 4 depola...
show more » |
| Absorption: | Little absorption from the gastrointestinal tract (40%). |
| Protein binding: | 20% |
| Half Life: | 36 hours |
| Toxicity: | Symptoms of overdose include ventricular tachycardia, ventricular fibrillation, progressive bradyarrhythmias, or heart block. |
| Affected organisms: | Humans and other mammals |
Interactions
| Drug interaction: |
|
|---|
Targets
